Patients with implanted cardiac devices who take sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs commonly prescribed for type 2 diabetes and heart failure, may experience an increased risk of atrial high-rate episodes (AHREs), according to a recent study. The findings, presented at the American Heart Association’s Scientific Sessions in November 2023, raise questions about the potential for these medications to trigger irregular heart rhythms in a vulnerable population. Understanding the nuances of this association is crucial for both patients and clinicians as SGLT2 inhibitors turn into increasingly integrated into standard cardiovascular care.
SGLT2 inhibitors—which include drugs like empagliflozin, dapagliflozin and canagliflozin—work by preventing the kidneys from reabsorbing glucose, leading to its excretion in the urine. This lowers blood sugar levels and has demonstrated benefits in reducing hospitalization for heart failure and cardiovascular death, as shown in landmark trials like EMPA-REG OUTCOME and DAPA-HF. The recent research, however, suggests a potential trade-off that warrants further investigation. The study focused specifically on patients with cardiac implantable electronic devices (CIEDs), such as pacemakers and defibrillators, which continuously monitor heart rhythm.
What the Study Found
Researchers analyzed data from over 1,400 patients with CIEDs who were taking SGLT2 inhibitors. They found that these patients experienced a significantly higher rate of AHREs—rapid, irregular heartbeats originating in the atria—compared to a control group of similar patients not taking the medications. Specifically, the study reported a 28% increase in the incidence of AHREs among those on SGLT2 inhibitors. The duration of AHREs was also longer in the SGLT2 inhibitor group. It’s important to note that the study established an association, not necessarily a direct causal link.
Dr. Jeffrey Heckman, lead author of the study and a cardiac electrophysiologist at Allegheny Health Network in Pittsburgh, emphasized the need for caution. “Even as SGLT2 inhibitors have proven benefits, our findings suggest a potential risk of atrial arrhythmias in patients with CIEDs,” he stated in a press release. “Further research is needed to confirm these findings and determine the underlying mechanisms.”
Who is Affected and Why This Matters
The findings are particularly relevant to the growing population of individuals with both diabetes and heart disease. The American Diabetes Association estimates that over 37.3 million Americans have diabetes, and a significant proportion of these individuals also have cardiovascular conditions. The prevalence of both conditions makes SGLT2 inhibitors a frequently prescribed medication. Patients with CIEDs represent a subset of those with heart disease who are already at risk for arrhythmias, and the study suggests that SGLT2 inhibitors may exacerbate this risk.
The mechanism behind this potential link remains unclear. Researchers hypothesize that SGLT2 inhibitors may alter atrial electrophysiology, making the heart more susceptible to irregular rhythms. Other potential explanations include changes in blood volume, electrolyte imbalances, or inflammation. The study did not find a correlation between the specific type of SGLT2 inhibitor used and the risk of AHREs.
Current Recommendations and Next Steps
Currently, major cardiology and diabetes organizations have not issued revised guidelines regarding SGLT2 inhibitor use based on this single study. However, clinicians are advised to be aware of the potential risk and to carefully monitor patients with CIEDs who are taking these medications. Monitoring may include more frequent checks of heart rhythm and evaluation for symptoms of atrial fibrillation, such as palpitations, shortness of breath, and fatigue.
“This is not a reason to stop taking these medications without talking to your doctor,” stresses Dr. Emily Stevenson, a cardiologist not involved in the study. “SGLT2 inhibitors have demonstrated significant benefits for many patients. However, it’s crucial to have an open discussion with your healthcare provider about the potential risks and benefits, especially if you have a CIED.”
Researchers are planning larger, randomized controlled trials to further investigate the association between SGLT2 inhibitors and AHREs. These trials will aim to establish whether the observed link is causal and to identify which patients are most vulnerable. The results of these studies are expected to provide more definitive guidance on the safe and effective use of SGLT2 inhibitors in patients with CIEDs. The FDA is currently reviewing the data and will likely issue a statement once a more comprehensive understanding of the risk is established.
For patients with questions or concerns about SGLT2 inhibitors and their heart health, the American Heart Association offers a wealth of information and resources on their website: www.heart.org. Regular communication with your healthcare team remains the most important step in managing your cardiovascular health.
Disclaimer: This article provides general medical information and should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
Share this article with anyone who might benefit from understanding the latest research on SGLT2 inhibitors and heart health. Your comments and questions are welcome below.
